Stilla Technologies

- GMO detection & quantification using high multiplexing Crystal Digital PCR and tolerance to inhibitors
- Going further- our next innovation- 6-color Crystal Digital PCR

Benefits of Crystal Digital PCR™ for Environmental and Food Testing

-Single assay quantification of more than 90% of known EGFR mutations

-Reliable and rapid detection of common mutations found in breast cancer

-Rectal cancer panel to detect and quantify PIK3CA mutations

By Kimberley Gutierrez & Viviane Sternkopf, application specialists (Stilla Technologies)

Liquid biopsy Quantification using 6-color Multiplexing for Cancer Panels

The commercialization of digital PCR platforms has sparked a revolution in quantitative nucleic acid detection over the past decade. Stilla Technologies’ Naica System, an established easy-to-use digital PCR platform, offers an innovative solution that quantifies in three colors while minimizing time to results.

This webinar will present the features of the company’s new 6-color Crystal Digital PCR System and highlight a set of applications poised to greatly benefit from the increased multiplexing and high sensitivity of 6-color digital PCR.

First, Alexandra Bogozalec from the National Institute of Biology in Slovenia will detail how her team has capitalized on the high-plex capacity of 6-color Crystal Digital PCR to simplify the time-consuming GMO quantification workflow and simultaneously quantify a set of genetically modified soybean lines at low target concentrations.

This webinar will also discuss how the highly sensitive detection capability of 6-color Crystal Digital PCR benefits oncology applications. Allison Mallory of Stilla Technologies will present high-plex mutation detection in non-small cell lung cancer, colorectal and breast cancer samples and will show how 6-color digital PCR enables efficient therapeutic monitoring and early detection of treatment resistance through noninvasive liquid biopsy.

By Alexandra Bogozalec Kosir, Research Assistant at the National Institute of Biology (Slovenia) & Allison Mallory, Director of Molecular Biology R&D at Stilla Technologies.

Innovation in Digital PCR: Maximizing Data Output from Precious Samples

The current gold standard for COVID-19 diagnosis is based on the detection of SARS-CoV-2 nucleic acid using real-time quantitative PCR (RT-qPCR). Recent studies suggest limitations of RT-qPCR in the detection of SARS-CoV-2, possibly leading to false-negative results. Development of robust and sensitive laboratory tests is of primary importance. Naica™ System is a Digital PCR platform offering absolute quantification of nucleic acids withvery high sensitivity and precision. Based on early and successful proof of concept in China, Stilla is developing a SARS-CoV-2 detection kit on the Naica™ System: a highly sensitive and internally controlled SARS-CoV-2 3-plex. It allows detection of two distinct regions: Nucleocapside (N) and ORF1ab genes of the SARS-CoV-2 positive-strand RNA genome, and an endogenous PCR reference detecting a human housekeeping gene. 
This single assay design permits the simultaneous detection of two independent SARS-CoV-2 sequences while concurrently monitoring sample PCR effectiveness. Due to its higher sensitivity, Crystal Digital PCR coupled with the detection kit for SARS-CoV-2 should be a perfect alternative to investigate non-conclusive high Ct results obtained in RT-qPCR.

By Romain Parillaud, PhD, International Application Specialist, Stilla Technologies

Highly Sensitive Crystal Digital PCR™ Detection Kit for SARS-CoV-2

Stilla Technologies talk was broadcast at EMBL Virtual Symposium: The Four-Dimension Genome (30-31st of March, 2020). <br/>Alexandra Martin, PhD., Application Specialist at Stilla Technologies walks you through Stilla's Crystal Digital PCR™ technology and its applications using the Naica™ System

Discover the simplicity of Digital PCR - Stilla Technologies at EMBL Virtual Symposium

Since the publication of the “The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments” (dMIQE) in 2013, there has been a large expansion of the applications of dPCR such as single nucleotide variations (SNVs) and copy number variations (CNVs) measurements associated with disease diagnostics. At the same time, international measurement organisations, such as the National Measurement Laboratory (NML) at LGC, have been working towards the development of molecular methods that are SI traceable to support the translation of these applications into the clinic. Digital PCR has the potential to be a traceable method as the concentration of a target is calculated based on the proportion of target-positive partitions and the application of Poisson statistics.

This webinar will focus on the use of dPCR for quantifying gene CNVs frequently used in diagnosis and selection of targeted therapy. Using models, like the HER2 gene in breast cancer, we will investigate the ability of dPCR to measure small changes in the gene copy number with further work to develop methods to counteract the measurement bias that can be caused by linked target copies in the sample. The talk will also highlight key dPCR performance parameters considered in the updated version of the dMIQE guidelines thereby fostering dPCR best practice and the use of dPCR as a gold standard approach.

By Alexandra Whale, PhD. in the National Measurement of the Laboratory (NML) hosted at LGC in collaboration with Stilla technologies & Genomeweb.

Stilla Technologies

Home

Videos

Playlists

About

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.